Imagine a world where we can offer hope to patients with relapsed and refractory multiple myeloma (MM), a disease that has spread beyond the bone marrow. Well, a recent study presented at the 2025 American Society of Hematology (ASH) Annual Meeting in Orlando, Florida, has shed light on a promising treatment combination. The combination of talquetamab (Tal) and teclistamab (Tec) is showing remarkable results for these challenging cases.
The RedirecTT-1 trial, a phase 2 study, evaluated the safety and effectiveness of this combination therapy in patients with triple-class exposed (TCE) relapsed/refractory MM and true extramedullary disease (EMD). Dr. Saad Usmani from the Memorial Sloan Kettering Cancer Center led the research, which included 90 patients with a median follow-up of 16.2 months.
But here's where it gets controversial: the study found that the treatment's efficacy varied based on the size of the EMD tumor. Patients with smaller tumors, less than 25 cm², experienced an impressive overall response rate (ORR) of 90.7%, with at least 60.5% achieving complete response (CR). However, as the tumor burden increased, the ORR declined, with patients having tumors over 50 cm² showing an ORR of 65.4% and a CR of only 30.8%.
In terms of safety, the combination was generally well-tolerated. No grade ≥3 cytokine release syndrome (CRS) was reported, and immune effector cell-associated neurotoxicity syndrome (ICANS) occurred in only 12.2% of patients, with a minimal percentage being grade ≥3. The most common side effects were low-grade taste changes, skin events, and nail changes.
The researchers concluded that the Tal + Tec combination outperformed all approved therapies for this high-burden, refractory MM population. They emphasized the clinical benefit for patients with true EMD, a group with significant unmet needs.
This study provides a glimmer of hope for patients with relapsed/refractory MM and EMD. However, the varying response rates based on tumor size raise questions about personalized treatment approaches. Should we tailor our treatments based on tumor characteristics? How can we optimize outcomes for all patients? These are questions that warrant further exploration and discussion.
What are your thoughts on this study's findings? Do you think personalized medicine is the future of cancer treatment? Share your insights and let's spark a conversation!
